Details of the Drug
General Information of Drug (ID: DMMDG92)
Drug Name |
Dodecyl-Alpha-D-Maltoside
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
DODECYL-ALPHA-D-MALTOSIDE; 116183-64-3; N-Dodecylmaltoside; Dodecyl a-D-maltopyranoside; n-Dodecyl alpha-D-maltoside; LMU; (2R,3R,4S,5S,6R)-2-(((2R,3S,4R,5R,6S)-6-(Dodecyloxy)-4,5-dihydroxy-2-(hydroxymethyl)tetrahydro-2H-pyran-3-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; AC1L9I0U; Dodecyl alpha-D-maltopyranoside; SCHEMBL17817178; Dodecyl-I+/--D-maltopyranoside; ZINC14253923; GC5636; AKOS030567697; DB03279; W0537; K-1145; 183D643; W-200893; dodecyl 4-O-alpha-D-glucopyranosyl-alpha-D-glucopyranoside
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 4 | Molecular Weight (mw) | 510.6 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 1.4 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 16 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 7 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 11 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||